Nandan Kulkarni, Director at Bernstein, has a message for investors still valuing Indian pharmaceutical companies purely on their US generics pipeline: that playbook is becoming obsolete. In a detailed conversation with ET Now, Kulkarni laid out why he believes Indian biopharma is at the beginning of a fundamental transformation — one that runs all the way to 2035 and remains significantly underpriced by the market.
